PACT Pharma
PACT Pharma is synthesizing neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each cancer patient.
All edits
Edits on 4 Dec, 2020
Edits made to:
Article (+14/-14 characters)
Article
PACT Pharma raised $95 million in Series B financing. Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin CapitalCasdin Capital, Wu Capital and other undisclosed investors.
Edits on 2 Dec, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Is a
Edits made to:
Infobox (+1 properties)
Infobox
Website
Edits on 17 Nov, 2018
Edits made to:
Article (+13/-13 characters)
Article
PACT Pharma raised $95 million in Series B financing. Alphabet Inc.Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.
Edits on 2 Oct, 2018
Edits made to:
Description (-37 characters)
Article (+2/-8 characters)
Categories (+1 topics)
PACT Pharma
PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient.
Article
The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.
Categories
Cluster: Synthetic biologyEdits on 21 Sep, 2018
Edits made to:
Description (+186 characters)
Article (+582 characters)
Related Topics (+2 topics)
PACT Pharma
PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient.
Article
The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.
PACT Pharma raised $95 million in Series B financing. Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.
Related Topics
Cancer cell
Immune systemEdits on 21 Sep, 2018
Edits made to:
PACT Pharma
PACT Pharma is synthesizing neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each cancer patient.
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.